| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15797f9d063307afcff503a86497fd23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5a3f9f17e4d4e16e76f21b630ab88f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbf165bb7ff2f583bad836698a7d9fe3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2006-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3148db64cd64b795cfe6b4f9f49880f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_243bc3607187a170db0c899a7fde82ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dd901f499c2e82da31e1958ce72b153 |
| publicationDate |
2012-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8129114-B2 |
| titleOfInvention |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| abstract |
EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015254433-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9753036-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10393748-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020125295-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10472682-B2 |
| priorityDate |
2005-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |